Patents Assigned to Washington Research Foundation
-
Patent number: 7353830Abstract: A composition or device suitable for orthopedic or dental implantation to bone, characterized by tartrate-resistant acid phosphatase (TRAP) adsorbed to a porous hydroxyapatite substratum.Type: GrantFiled: June 17, 2004Date of Patent: April 8, 2008Assignee: Washington Research FoundationInventors: Minako Yoshioka Lee, David Rodney Eyre, Mary Ann Eklof Weis
-
Publication number: 20070286860Abstract: Compositions and methods are provided for inducing anti-tumor immunity. More specifically, tumor cells and recombinant constructs are provided that express a cell surface CD83 polypeptide and/or a cell surface expressed antibody that specifically binds to an immune cell receptor, particularly an antibody that specifically binds to CD137. The invention also provides recombinant expression constructs comprising polynucleotides that encode a cell surface CD83 polypeptide, a cell surface expressed anti-immune cell receptor antibody, and/or at least one tumor antigen, and the related expressed products.Type: ApplicationFiled: March 25, 2005Publication date: December 13, 2007Applicant: Washington Research FoundationInventors: Karl Hellstrom, Ingegerd Hellstrom, Yi Yang
-
Patent number: 6916604Abstract: Peptides synthesized to match the human ?1 (I) and ?2 (I) amino-telopeptide sequences of type I collagen degradation products in body fluids, preferably either Asp-GIu-Lys-Ser-Thr-Gly-Gly (SEQ ID NO:5) or Gln-Tyr-Asp-Gly-Lys-Gly-Val-Gly (SEQ ID NO:6). used as calibrators and antigens in immunoassays for detecting type I collagen degradation products in body fluids.Type: GrantFiled: March 7, 2003Date of Patent: July 12, 2005Assignee: Washington Research FoundationInventor: David R. Eyre
-
Patent number: 6916903Abstract: Peptides synthesized to match C-telopeptide components of type III collagen degradation products in body fluids, selected from among EKAGGF (SEQ ID NO:39), IGGEKAGG (SEQ ID NO:40), IGGEKAGGF (SEQ ID NO:41), IAGIGGEKAGG (SEQ ID NO:42), IAGIGGEKAGGF (SEQ ID NO:43), and EKAGG (SEQ ID NO:44) are useful as immunogens and antigens in collagen resorption assays.Type: GrantFiled: July 8, 2003Date of Patent: July 12, 2005Assignee: Washington Research FoundationInventor: David R. Eyre
-
Patent number: 6887659Abstract: A method for assaying bone resorption rates which consists of quantitating the concentration of peptide fragments derived from bone collagen, found in a body fluid is disclosed. The method includes immunometric assay, fluorometric assay and electrochemical titration. The structure of specific peptide fragments having 3-hydroxypyridinium cross-links found in urine of Paget's disease patients and procedures for making monoclonal antibodies is described.Type: GrantFiled: January 17, 2003Date of Patent: May 3, 2005Assignee: Washington Research FoundationInventor: David R. Eyre
-
Publication number: 20040235070Abstract: Methods for the detection, monitoring and treatment of malignancies are disclosed. Detection of the proliferation of T cells in response to in vitro exposure to a protein expression product of an activated oncogene or cancer-related gene associated with a malignancy, or detection of immunocomplexes formed between the protein expression product and antibodies in body fluid, allows the diagnosis of the presence of a malignancy. The present invention also discloses methods and compositions for treating a malignancy.Type: ApplicationFiled: September 24, 2003Publication date: November 25, 2004Applicant: Washington Research FoundationInventors: Martin A. Cheever, David J. Peace
-
Publication number: 20040228899Abstract: A composition or device suitable for orthopedic or dental implantation to bone, characterized by tartrate-resistant acid phosphatase (TRAP) adsorbed to a porous hydroxyapatite substratum.Type: ApplicationFiled: June 17, 2004Publication date: November 18, 2004Applicant: Washington Research FoundationInventors: Minako Yoshioka Lee, David Rodney Eyre, Mary Ann Eklof Weis
-
Publication number: 20040048321Abstract: Peptides synthesized to match telopeptide components of type III collagen degradation products in body fluids, selected from among DVKSGVAVGG (SEQ ID NO:33), YDVKSGVAVGG (SEQ ID NO:34), SYDVKSGVAVGG (SEQ ID NO:35), DSYDVKSGVAVGG (SEQ ID NO:36), JYDSYDVKSGVAVGG (SEQ ID NO:37), EKAGGF (SEQ ID NO:39), IGGEKAGG (SEQ ID NO:40), IGGEKAGGF (SEQ ID NO:41), IAGIGGEKAGG (SEQ ID NO:42), and IAGIGGEKAGGF (SEQ ID NO:43) are useful as immunogens and antigens in collagen resorption assays.Type: ApplicationFiled: July 8, 2003Publication date: March 11, 2004Applicant: Washington Research FoundationInventor: David R. Eyre
-
Publication number: 20040009531Abstract: A method for assaying bone resorption rates which consists of quantitating the concentration of peptide fragments derived from bone collagen, found in a body fluid is disclosed. The method includes immunometric assay, fluorometric assay and electrochemical titration. The structure of specific peptide fragments having 3-hydroxypyridinium cross-links found in urine of Paget's disease patients and procedures for making monoclonal antibodies is described.Type: ApplicationFiled: January 17, 2003Publication date: January 15, 2004Applicant: Washington Research FoundationInventor: David R. Eyre
-
Publication number: 20030166032Abstract: Immunoassays for measuring type II collagen (cartilage) resorption in vivo employ either one or two antibodies. A first antibody binds to DEKAGGA (SEQ ID NO:21) but not to GGFDEKAGGAQLG (SEQ ID NO:27), where the K symbols refer to lysine or preferably to cross-linking 3-hydroxypyridinium residues. Measurement of analyte binding to the first antibody in serum provides an indication of unmineralized cartilage resorption in vivo. A second antibody binds to GGFDEKAGGAQLG but not to DEKAGGA. Measurement of analyte binding to the second antibody in serum provides an indication of mineralized cartilage resorption in vivo. An indication of total (unmineralized and mineralized) cartilage resorption in vivo is provided by either measurement of analyte binding to the first antibody in urine, or by measurement of the total analyte binding to the first and second antibodies in serum.Type: ApplicationFiled: April 3, 2003Publication date: September 4, 2003Applicant: Washington Research FoundationInventor: David R. Eyre
-
Publication number: 20030166033Abstract: Methods of determining collagen degradation in vivo, by quantitating the concentration of a peptide in a body fluid, the peptide being a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or a type III collagen telopeptide containing a hydroxylysyl pyridinoline cross-link. Suitable methods include immunometric assays, fluorometric assays, and electrochemical titrations for quantitation. The structures of specific peptides having cross-links and kits for quantitating these peptides in a body fluid are described.Type: ApplicationFiled: March 7, 2003Publication date: September 4, 2003Applicant: Washington Research FoundationInventor: David R. Eyre
-
Patent number: 6602980Abstract: Peptides synthesized to match N-telopeptide components of type III collagen degradation products in body fluids, selected from among DVKSGVAVGG (SEQ ID NO 33), YDVKSGVAVGG (SEQ ID NO 34), SYDVKSGVAVGG (SEQ ID NO 35), DSYDVKSGVAVGG (SEQ ID NO 36), JYDSYDVKSGVAVGG (SEQ ID NO 37), and KSGVAVGG (SEQ ID NO 45) are claimed. The peptides are useful as immunogens and antigens in collagen resorption assays.Type: GrantFiled: July 1, 2002Date of Patent: August 5, 2003Assignee: Washington Research FoundationInventor: David R. Eyre
-
Patent number: 6566492Abstract: The claimed invention is peptides synthesized to match telopeptide components of type II collagen degradation products in synovial fluid and blood, selected from among LGPREKGPDP (SEQ ID NO 11), LGPREKGPDPLQ (SEQ ID NO 12), LGPREKGPDPLQY (SEQ ID NO 13), FAGLGPREKGPDP (SEQ ID NO 14), FAGLGPREKGPDPLQ (SEQ ID NO 15), FAGLGPREKGPDPLQY (SEQ ID NO 16), IDMSAFAGLGPREKGPDP (SEQ ID NO 17), IDMSAFAGLGPREKGPDPLQ (SEQ ID NO 18), IDMSAFAGLGPREKGPDPLQY (SEQ ID NO 19), and EKGPDPLQYMR (SEQ ID NO 20), which maybe useful as immunogens and antigens in cartilage resorption assays.Type: GrantFiled: February 11, 2002Date of Patent: May 20, 2003Assignee: Washington Research FoundationInventor: David R. Eyre
-
Publication number: 20030036799Abstract: A composition or device suitable for orthopedic or dental implantation to bone, characterized by tartrate-resistant acid phosphatase (TRAP) adsorbed to a porous hydroxyapatite substratum.Type: ApplicationFiled: September 27, 2002Publication date: February 20, 2003Applicant: Washington Research FoundationInventors: Minako Yoshioka Lee, David Rodney Eyre, Mary Ann Eklof Weis
-
Patent number: 6508838Abstract: A composition or device suitable for orthopedic or dental implantation to bone, characterized by tartrate-resistant acid phosphatase (TRAP) adsorbed to a porous hydroxyapatite substratum.Type: GrantFiled: February 16, 2001Date of Patent: January 21, 2003Assignee: Washington Research FoundationInventors: Minako Yoshioka Lee, David Rodney Eyre, Mary Ann Eklof Weis
-
Patent number: 6509450Abstract: An immunoassay kit for the quantification of degradation products of carboxy-terminal telopeptides of type I collagen in a human serum sample, including an antibody that is characterized by binding to at least one peptide derived from the carboxy-terminal telopeptide domain of type I collagen and isolatable from a urine sample of a patient with active Patet's disease.Type: GrantFiled: March 19, 2001Date of Patent: January 21, 2003Assignee: Washington Research FoundationInventor: David R. Eyre
-
Publication number: 20020182639Abstract: Immunoassays for measuring type II collagen (cartilage) resorption in vivo employ either one or two antibodies. A first antibody binds to DEKAGGA (SEQ ID NO:21) but not to GGFDEKAGGAQLG (SEQ ID NO:27), where the K symbols refer to lysine or preferably to cross-linking 3-hydroxypyridinium residues. Measurement of analyte binding to the first antibody in serum provides an indication of unmineralized cartilage resorption in vivo. A second antibody binds to GGFDEKAGGAQLG but not to DEKAGGA. Measurement of analyte binding to the second antibody in serum provides an indication of mineralized cartilage resorption in vivo. An indication of total (unmineralized and mineralized) cartilage resorption in vivo is provided by either measurement of analyte binding to the first antibody in urine, or by measurement of the total analyte binding to the first and second antibodies in serum.Type: ApplicationFiled: February 11, 2002Publication date: December 5, 2002Applicant: Washington Research FoundationInventor: David R. Eyre
-
Patent number: 6348320Abstract: Immunoassays for measuring type II collagen (cartilage) resorption in vivo employ either one or two antibodies. A first antibody binds to DEKAGGA (SEQ ID NO:21) but not to GGFDEKAGGAQLG (SEQ ID NO:27), where the K symbols refer to lysine or preferably to cross-linking 3-hydroxypyridinium residues. Measurement of analyte binding to the first antibody in serum provides an indication of unmineralized cartilage resorption in vivo. A second antibody binds to GGFDEKAGGAQLG but not to DEKAGGA. Measurement of analyte binding to the second antibody in serum provides an indication of mineralized cartilage resorption in vivo. An indication of total (unmineralized and mineralized) cartilage resorption in vivo is provided by either measurement of analyte binding to the first antibody in urine, or by measurement of the total analyte binding to the first and second antibodies in serum.Type: GrantFiled: August 30, 1999Date of Patent: February 19, 2002Assignee: Washington Research FoundationInventor: David R. Eyre
-
Publication number: 20010016203Abstract: A composition or device suitable for orthopedic or dental implantation to bone, characterized by tartrate-resistant acid phosphatase (TRAP) adsorbed to a porous hydroxyapatite substratum.Type: ApplicationFiled: February 16, 2001Publication date: August 23, 2001Applicant: Washington Research FoundationInventors: Minako Yoshioka Lee, David Rodney Eyre, Mary Ann Eklof Weis
-
Patent number: 6255056Abstract: Immunoassays for measuring type II collagen (cartilage) resorption in vivo employ either one or two antibodies. A first antibody binds to EKGPDP (SEQ ID NO:2) but not to EKGPDPLQ (SEQ ID NO:10), where the K symbols refer to lysine or preferably to cross-linking 3-hydroxypyridinium residues. Measurement of analyte binding to the first antibody in serum provides an indication of unmineralized cartilage resorption in vivo. A second antibody binds to EKGPDPLQ (SEQ ID NO:10) but not to EKGPDP (SEQ ID NO:2). Measurement of analyte binding to the second antibody in serum provides an indication of mineralized cartilage resorption in vivo. An indication of total (unmineralized and mineralized) cartilage resorption in vivo is provided by either measurement of analyte binding to the first antibody in urine, or by measurement of the total analyte binding to the first and second antibodies in serum.Type: GrantFiled: June 17, 1999Date of Patent: July 3, 2001Assignee: Washington Research FoundationInventor: David R. Eyre